Kanglin Biotechnology
Develops innovative gene therapies for serious diseases like AIDS, Parkinson's, hemophilia, and thalassemia
About Kanglin Biotechnology
Kanglin Biotechnology (Hangzhou) Co., Ltd., founded in 2015, is a clinical-stage biopharmaceutical company focused on developing and commercializing gene therapies. The company was established by Dr. Haoquan Wu, who serves as the CEO. Dr. Wu has an extensive academic and research background, holding a Ph.D. from Fudan University, followed by postdoctoral positions at UCLA and Harvard University, and faculty positions at Texas Tech University before dedicating himself full-time to Kanglin Biotechnology.
The company's primary objective is to create first-in-class and best-in-class gene therapy drugs to address severe diseases with significant unmet medical needs. Its therapeutic pipeline targets conditions such as beta thalassemia, sickle cell disease, AIDS, Parkinson's disease, and hemophilia. Kanglin Biotechnology operates in the advanced therapies market, developing treatments that have the potential to offer one-time curative interventions for patients.
The firm's lead product candidate, KL003, is a lentiviral vector gene therapy designed for the treatment of transfusion-dependent beta thalassemia and sickle cell disease. This therapy works by delivering a functional ß-globin gene in a single treatment. Clinical trials have shown promising results, with a Phase 1 study demonstrating 100% efficacy in 17 patients, leading to faster transfusion independence and engraftment compared to other gene therapies. KL003 has received both Orphan Drug Designation (ODD) and Pediatric Rare Disease Designation (PRDD) from the U.S. Food and Drug Administration (FDA), and its clinical trial application was approved by China's Center for Drug Evaluation (CDE) in January 2024. A key differentiator for KL003 is its significantly reduced manufacturing cost compared to currently available gene therapies, which could improve patient access to the treatment.
Kanglin Biotechnology's business model is centered on the research, development, and eventual commercialization of its proprietary gene therapies. The company has secured significant funding to advance its clinical pipeline, including a $20 million Series A round to support the development of KL003 and other pipeline candidates. The company has established a GMP-compliant cell production line to meet both clinical and future commercial manufacturing demands. It actively seeks strategic partnerships for clinical research in areas including infectious diseases, neurodegenerative diseases, monogenic hereditary diseases, and ophthalmology.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Employees
- 16
- Open positions
- None listed
- Dealroom signal
- 24.0/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotechnology, Gene Therapy, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Nov 2024 | $20M | $80M | Undisclosed | ↗ |
| SPINOUT✓Other financing | Jan 2015 | $0 | — | Texas Tech University | — |
Growth signals
Latest recorded traffic for Kanglin Biotechnology is 1.6K monthly website visits, up 110.5% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Kanglin Biotechnology in the Hangzhou ecosystem
The Kanglin Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Other known investors1 additional known investor
Texas Tech University
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Kanglin Biotechnology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Kanglin Biotechnology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










